(Reuters) – An AstraZeneca AZN.L The executive said the COVID-19 vaccine trial data unveiled by Pfizer and its German partner Bioentech was encouraged by those who “promise with confidence”, while hopefully the United States will accept the innovation under the next administration.
Speaking at the Financial Times conference online conference on healthcare on Monday, Rud Dobre, a member of AstraZeneca’s senior executive team, said the first set of large-scale study effectiveness data had made him optimistic that AstraZeneca would follow suit. Trial in the early stages.
U.S. Drugmaker Pfizer P.F.E.N. And bayonet tech 22UAy.f. The experimental vaccine was shown to be more than 90% effective based on the initial phase trial results, the companies said earlier in the day.
AstraZeneca, a British drugmaker working at the University of Oxford, expects trial data for the next phase of its Covid-19 vaccination before the end of the year.
“What we’ve seen in the first phase and the second phase – whether it’s Pfizer or Astrazeneca with our Oxford vaccine – is that if you’re able to produce neutral antibodies and a good T-cell response so you can make the virus less hostile, Dobre said.
He added, “The effectiveness shown today is incredibly promising and I hope that more vaccine manufacturers will sooner or later show similar results,” he added.
Many, including US President Donald Trump and President-elect Joe Biden, welcomed the results of Pfizer / Bioentech, both of which have taken very different approaches to tackling epidemics and general health care.
Dober’s message to Biden and his administration was: “Accept innovation, be critical, but accept innovation … let’s find a dialogue and let’s not fight more about political color.”
Biden said Monday that the coronavirus vaccine approval procedure must be guided by science, warning that the vaccine will not be available for months.
Dobre also added that he expects to strengthen the Affordable Care Act under Biden, who, when he was vice president in the Obama administration, spoke highly of the benefits of the program, which was implemented in 2010.
Reported by Ludwig Burger in Frankfurt and Pushkala Aripaka in Bengaluru; Edited by John Harvey and Alistair Bell
Freelance twitter maven. Infuriatingly humble coffee aficionado. Amateur gamer. Typical beer fan. Avid music scholar. Alcohol nerd.